Gadoteridol
Prohance (gadoteridol) is a small molecule pharmaceutical. Gadoteridol was first approved as Prohance on 1992-11-16.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Gadoteridol, Prohance, Prohance multipack
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Gadoteridol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PROHANCE | Bracco Diagnostics | N-020131 RX | 1992-11-16 | 1 products, RLD, RS |
| PROHANCE MULTIPACK | Bracco Diagnostics | N-021489 RX | 2003-10-09 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| prohance | New Drug Application | 2024-12-02 |
| prohance multipack | 2006-04-13 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| A9576 | Injection, gadoteridol, (prohance multipack), per ml |
Clinical
Clinical Trials
21 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Brain diseases | D001927 | — | G93.40 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system neoplasms | D016543 | — | — | — | — | — | — | 1 | 1 |
| Central nervous system diseases | D002493 | — | G96.9 | — | — | — | — | 1 | 1 |
| Nervous system diseases | D009422 | — | G00-G99 | — | — | — | — | 1 | 1 |
| Nervous system neoplasms | D009423 | — | — | — | — | — | — | 1 | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 1 | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 1 | 1 |
| Renal insufficiency | D051437 | — | N19 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Gadoteridol |
| INN | gadoteridol |
| Description | Gadoteridol (INN) is a gadolinium-based MRI contrast agent, used particularly in the imaging of the central nervous system. It is sold under the brand name ProHance. Gadoteridol was first approved for use in the United States in 1992.
|
| Classification | Small molecule |
| Drug class | gadolinium derivatives (principally for diagnostic use) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 120066-54-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200593 |
| ChEBI ID | 31643 |
| PubChem CID | 60714 |
| DrugBank | DB00597 |
| UNII ID | 0199MV609F (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,355 documents
View more details
Safety
Black-box Warning
Black-box warning for: Prohance
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,030 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use